Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors

• Main Authors: Lukas Fiedler (Author), Lukas J. Motloch (Author), Anna-Maria Dieplinger (Author), Peter Jirak (Author), Paruir Davtyan (Author), Diana Gareeva (Author), Elena Badykova (Author), Marat Badykov (Author), Irina Lakman (Author), Aleksandr Agapitov (Author), Liana Sadikova (Author), Valentin Pavlov (Author), Fabian Föttinger (Author), Moritz Mirna (Author), Kristen Kopp (Author), Uta C. Hoppe (Author), Rudin Pistulli (Author), Benzhi Cai (Author), Baofeng Yang (Author), Naufal Zagidullin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: While acute Coronavirus disease 2019 (COVID-19) affects the cardiovascular (CV) system according to recent data, an increased CV risk has been reported also during long-term follow-up (FU). In addition to other CV pathologies in COVID-19 survivors, an enhanced risk for arrhythmic event...